Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) have received an average recommendation of “Moderate Buy” from the seven ratings firms that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company.

BIOVF has been the topic of a number of recent analyst reports. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Pareto Securities downgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Monday, June 29th. HC Wainwright started coverage on Swedish Orphan Biovitrum in a report on Wednesday, May 6th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Swedish Orphan Biovitrum in a research report on Tuesday, July 21st. Finally, Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a report on Friday, July 3rd.

Swedish Orphan Biovitrum Stock Performance

Shares of BIOVF opened at $48.20 on Monday. The company has a market capitalization of $17.16 billion, a PE ratio of 107.12 and a beta of 0.35. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.88 and a quick ratio of 0.55. Swedish Orphan Biovitrum has a one year low of $28.93 and a one year high of $49.03. The company’s fifty day moving average price is $48.32 and its 200 day moving average price is $43.90.

Swedish Orphan Biovitrum Company Profile

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.